Monday, February 13, 2012

Canadian Generic Drug Market to be Worth CAD 9.4 Billion by 2013 by Shushmul Maheshwari

According to our latest market research report entitled “Generic Drug Market in Canada”, Canadian generic drug sector represents one of the fastest growing opportunities in the pharmaceutical industry. In 2009, the generic drugs market reached to the mark of CAD 5.47 Billion backed by factors like, patent expiration of branded drugs and government support through cost-cutting measures. The market is expected to grow at the CAGR of more than 14% during 2009-2013 to reach around CAD 9.4 Billion by the end of 2013.

Our report has found that cardiovascular drug market is one of the most vibrant sectors in Canadian pharmaceutical industry. Both the prescription and sales related to cardiovascular drugs have been increasing and given the fact that, many drugs will lose their patents in future, the market is expected to grow further. In 2009, the total sales of cardiovascular drugs reached CAD 3.3 Billion, which is expected to be worth around CAD 4.1 Billion by 2013.

The report “Generic Drug Market in Canada” has analyzed Canadian generics market in a prudent manner, taking into account key facets of industry and growth drivers. The report has also covered current market trends that have had a positive impact on the sector recently and that are expected to back the sector in near future. The report has used reliable statistics and presented information in an effective manner, using easy-to-understand language and presentation.

The report provides extensive research and objective analysis of Canadian generic drugs market. Coverage of market performance section evaluates the sector from the perspective of key factors. These factors are related to various distribution channels, disease categories, provinces, etc. Market forecast presents future outlook of the industry and the use of reliable methods and techniques make the projection more realistic. Description and key activities of market players have also been covered. Overall, the report is expected to be a key portfolio of knowledge and analysis for clients and investors.

For FREE SAMPLE of this report visit: